• Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation about where the Company will spend the money.

  • Another significant acquisition could be next. Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) is a prime potential buyout target for Novartis, Bloomberg reported, citing people with knowledge of the matter.

  • Alnylam is the developer of the RNA interference (RNAi) technology behind Novartis' newly acquired cholesterol drug Leqvio (inclisiran).

  • The revelation follows Novo Nordisk A/S's (NYSE: NVO) announcement that it is shelling out .3 billion to purchase clinical-stage RNAi biotech Dicerna Pharmaceuticals Inc (NASDAQ: DRNA).

  • The report added that Vertex Pharmaceuticals Inc (NASDAQ: VRTX), Intellia Therapeutics Inc (NASDAQ: NTLA), Biogen Inc (NASDAQ: BIIB), Incyte Corp (NASDAQ: INCY), and BioMarin Pharmaceutical Inc (NASDAQ: BMRN) are among a range of other companies seen as potential targets.

  • Also Read: Novartis Mulls Strategic Options For Sandoz, Reaffirms FY21 Outlook.

  • Price Action: ALNY shares are up 4.60% at $180.68 during the market session on the last check Thursday.

See more from Benzinga

  • Click here for options trades from Benzinga

  • Novo Nordisk Swallows Dicerna In .3B Buyout: All You Need To Know

  • Spark Therapeutics' Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

(305) 707 0888